Elite Journal of Health Sciences. Volume 2 issue 3(2024), Pp. 44-52
https://epjournals.com/journals/EJHS

# Oxidative Imbalance in Sickle Cell Disease: Unraveling the Molecular Mechanisms

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

## Abstract

Sickle cell disease (SCD) stands as one of the most prevalent genetic disorders globally, characterized by the abnormal hemoglobin S (HbS) leading to distorted erythrocyte morphology and consequent microvascular occlusion, hemolysis, and tissue ischemia. Despite advancements in understanding its pathophysiology, the mechanisms underlying the oxidative imbalance observed in SCD remain intricate and multifaceted. This review elucidates the molecular intricacies contributing to oxidative stress in SCD, emphasizing the interplay between aberrant erythrocyte function, inflammation, and vascular dysfunction. Reactive oxygen species (ROS) production stemming from autoxidation of HbS and activation of leukocytes, endothelial cells, and platelets exacerbates oxidative stress, perpetuating a vicious cycle of cellular damage and inflammation. Moreover, impaired antioxidant defense mechanisms further augment oxidative burden, compromising cellular integrity and function. Recent research highlights the involvement of redox-sensitive signaling pathways, such as nuclear factor erythroid 2-related factor 2 (Nrf2), in modulating oxidative responses in SCD, offering potential therapeutic targets to ameliorate oxidative damage and its downstream complications. Additionally, emerging evidence suggests a bidirectional relationship between oxidative stress and dysregulated nitric oxide (NO) bioavailability, contributing to endothelial dysfunction and vaso-occlusive events in SCD.

***Keywords***: *Sickle cell disease, oxidative stress, reactive oxygen species, antioxidant defense, molecular mechanisms*

## Introduction

Sickle cell disease (SCD) represents a prevalent inherited hemoglobinopathy characterized by the presence of abnormal hemoglobin S (HbS), leading to erythrocyte deformation, microvascular occlusion, and systemic complications. While SCD primarily manifests as a hematologic disorder,

mounting evidence underscores the pivotal role of oxidative stress in its pathogenesis. Oxidative stress results from the imbalance between the production of reactive oxygen species (ROS) and the antioxidant defense mechanisms, culminating in cellular damage and dysfunction. In SCD, the delicate equilibrium between oxidant production and antioxidant capacity is perturbed, exacerbating disease severity and clinical manifestations. Despite considerable advancements in understanding the molecular basis of SCD, the intricate interplay between oxidative stress and disease pathophysiology remains incompletely elucidated. The etiology of oxidative stress in SCD is multifactorial, encompassing diverse cellular processes and molecular pathways. A primary contributor to ROS generation in SCD is the autoxidation of HbS, facilitated by the inherent instability of sickle erythrocytes and the presence of intracellular hemichromes. Additionally, activated leukocytes, endothelial cells, and platelets further fuel ROS production through various mechanisms, including the release of inflammatory mediators, adhesion molecule expression, and endothelial dysfunction. Consequently, the heightened oxidative burden perpetuates a cycle of cellular injury, inflammation, and vaso-occlusive events, amplifying disease complications and organ damage.[1-22]

Compromised antioxidant defense mechanisms in SCD exacerbate oxidative stress, exacerbating disease severity and clinical outcomes. While erythrocytes possess intrinsic antioxidant systems, including superoxide dismutase and catalase, their efficacy is often compromised in SCD due to increased ROS production and oxidative damage. Furthermore, diminished levels of endogenous antioxidants, such as glutathione and vitamin E, further exacerbate oxidative stress, exacerbating cellular vulnerability to oxidative injury. The dysregulation of redox-sensitive transcription factors, such as nuclear factor erythroid 2-related factor 2 (Nrf2), further contributes to impaired antioxidant responses, perpetuating oxidative imbalance in SCD. Emerging evidence suggests a bidirectional relationship between oxidative stress and dysregulated nitric oxide (NO) bioavailability in SCD, further exacerbating endothelial dysfunction and vaso-occlusive phenomena. Reduced NO bioavailability, stemming from increased NO scavenging by ROS and impaired endothelial NO synthase function, contributes to aberrant vasomotor tone, platelet activation, and leukocyte adhesion, exacerbating vaso-occlusive crises and tissue ischemia. Conversely, NO-derived ROS production further perpetuates oxidative stress, creating a vicious cycle of endothelial dysfunction and oxidative damage in SCD. Understanding the intricate interplay between oxidative stress and NO bioavailability is paramount for developing targeted therapeutic interventions aimed at ameliorating endothelial dysfunction and vaso-occlusive complications in SCD.[23-55]

**Oxidative Stress in Sickle Cell Disease**

Oxidative stress plays a pivotal role in the pathophysiology of sickle cell disease (SCD), a hereditary hemoglobinopathy characterized by the presence of abnormal hemoglobin S (HbS).[56] The hallmark of SCD is the polymerization of deoxygenated HbS, leading to distorted erythrocyte morphology, reduced deformability, and increased susceptibility to hemolysis. This aberrant erythrocyte physiology contributes to microvascular occlusion, tissue ischemia, and systemic complications, highlighting the multifaceted nature of the disease. Amidst this complexity, oxidative stress emerges as a key mediator of cellular injury and inflammation in SCD. The

primary source of oxidative stress in SCD stems from the autoxidation of HbS, whereby deoxygenated HbS molecules undergo oxidation, generating reactive oxygen species (ROS) such as superoxide anion radicals and hydrogen peroxide. These ROS contribute to cellular damage by oxidizing lipids, proteins, and nucleic acids, disrupting cellular integrity and function. Moreover, the presence of intracellular hemichromes, resulting from HbS denaturation and heme release, further exacerbates oxidative stress, fueling a vicious cycle of erythrocyte damage and hemolysis in SCD.

Beyond erythrocytes, activated leukocytes, endothelial cells, and platelets also contribute to ROS production in SCD through inflammatory responses and adhesion molecule expression.[57] Leukocyte activation releases pro-inflammatory cytokines and chemokines, amplifying oxidative stress and promoting vascular inflammation. Endothelial dysfunction, characterized by impaired nitric oxide (NO) bioavailability and increased adhesion molecule expression, further exacerbates oxidative stress by promoting leukocyte adhesion and vaso-occlusion. Platelet activation in SCD not only enhances thrombotic events but also contributes to ROS production through NADPH oxidase activation, perpetuating oxidative stress and endothelial dysfunction. Consequently, the delicate balance between oxidant production and antioxidant defense mechanisms is disrupted in SCD, resulting in a state of chronic oxidative stress. While erythrocytes possess intrinsic antioxidant systems, including superoxide dismutase and catalase, their efficacy is often overwhelmed by the heightened ROS production in SCD. Moreover, diminished levels of endogenous antioxidants, such as glutathione and vitamin E, further compromise cellular antioxidant capacity, exacerbating oxidative damage and inflammation. The repercussions of oxidative stress extend beyond erythrocyte damage, contributing to vaso-occlusive crises, tissue injury, and organ damage in SCD. Chronic oxidative stress promotes endothelial dysfunction, thrombosis, and inflammation, perpetuating a cycle of vascular injury and ischemia. Understanding the intricate mechanisms underlying oxidative stress in SCD is essential for developing targeted therapeutic interventions aimed at mitigating oxidative damage, preserving endothelial function, and improving clinical outcomes for individuals afflicted with this debilitating disorder.

**Molecular Mechanisms of Oxidative Imbalance**

The molecular mechanisms underlying oxidative imbalance in sickle cell disease (SCD) are multifaceted and involve intricate interplays between various cellular components and signaling pathways.[58] At the core of oxidative imbalance lies the aberrant behavior of sickle erythrocytes, characterized by the presence of abnormal hemoglobin S (HbS) and the ensuing oxidative stress resulting from its polymerization. Here, we delve into the molecular intricacies driving oxidative imbalance in SCD, highlighting key players and pathways involved. Autoxidation of deoxygenated HbS represents a primary source of reactive oxygen species (ROS) in SCD. Upon deoxygenation, HbS molecules undergo polymerization, leading to the formation of rigid, sickle-shaped erythrocytes. This structural alteration renders sickle erythrocytes susceptible to oxidative damage, facilitating the release of hemoglobin and heme into the intracellular milieu. Subsequently, free heme catalyzes the generation of ROS via Fenton-like reactions, exacerbating oxidative stress and cellular injury.

In addition to erythrocyte-derived ROS, activated leukocytes, endothelial cells, and platelets contribute to oxidative imbalance in SCD through inflammatory responses and adhesion molecule expression.[59] Leukocyte activation releases pro-inflammatory cytokines and chemokines, stimulating ROS production via NADPH oxidase activation. Endothelial dysfunction, characterized by reduced nitric oxide (NO) bioavailability and increased adhesion molecule expression, further amplifies oxidative stress by promoting leukocyte adhesion and vaso-occlusion. Platelet activation in SCD not only enhances thrombotic events but also contributes to ROS production through NADPH oxidase activation, perpetuating oxidative stress and endothelial dysfunction. Impaired antioxidant defense mechanisms in SCD further exacerbate oxidative imbalance, compromising cellular integrity and function. While erythrocytes possess intrinsic antioxidant systems, including superoxide dismutase and catalase, their efficacy is often overwhelmed by the heightened ROS production in SCD. Furthermore, diminished levels of endogenous antioxidants, such as glutathione and vitamin E, further compromise cellular antioxidant capacity, exacerbating oxidative damage and inflammation. Redox-sensitive signaling pathways, such as nuclear factor erythroid 2-related factor 2 (Nrf2), play a crucial role in modulating oxidative responses in SCD. Nrf2 serves as a master regulator of antioxidant gene expression, orchestrating the cellular defense against oxidative stress. Dysregulation of Nrf2 signaling in SCD contributes to impaired antioxidant responses, perpetuating oxidative imbalance and exacerbating disease severity.

**Therapeutic Implications**

Understanding the molecular mechanisms driving oxidative imbalance in sickle cell disease (SCD) offers crucial insights for the development of targeted therapeutic interventions aimed at mitigating oxidative damage and improving clinical outcomes for affected individuals. Given the central role of oxidative stress in SCD, antioxidant therapy represents a promising approach to counteract ROS-mediated damage.[60] Antioxidants such as N-acetylcysteine (NAC), vitamin E, and ascorbic acid have shown potential in preclinical and clinical studies for their ability to scavenge ROS and restore redox balance. These agents may help alleviate oxidative damage to erythrocytes, endothelial cells, and other tissues, thereby reducing inflammation, vaso-occlusive events, and organ damage in SCD. Redox-sensitive transcription factors, such as nuclear factor erythroid 2-related factor 2 (Nrf2), play a critical role in regulating cellular antioxidant defenses and maintaining redox homeostasis. Pharmacological activators of Nrf2, such as dimethyl fumarate (DMF) and bardoxolone methyl, have demonstrated potential in preclinical models of SCD by upregulating antioxidant genes and attenuating oxidative stress-induced damage. Modulating Nrf2 signaling represents a promising therapeutic strategy for enhancing endogenous antioxidant capacity and mitigating oxidative imbalance in SCD.

Dysregulated NO bioavailability contributes to endothelial dysfunction and vaso-occlusive complications in SCD.[61] Therapeutic approaches aimed at restoring NO levels or enhancing NO-mediated signaling pathways hold promise for improving vascular function and reducing disease severity in SCD. Pharmacological agents such as hydroxyurea, L-arginine supplementation, and NO donors have shown beneficial effects in preclinical and clinical studies by promoting vasodilation, inhibiting platelet activation, and reducing vaso-occlusive events. Optimizing NO

bioavailability represents a rational therapeutic approach for mitigating oxidative stress and improving microvascular function in SCD. Inflammation plays a central role in SCD pathophysiology, contributing to oxidative stress, endothelial dysfunction, and vaso-occlusive events. Targeting inflammatory pathways and cytokines implicated in SCD-associated inflammation may help alleviate oxidative stress and reduce disease complications. Anti-inflammatory agents such as corticosteroids, hydroxyurea, and novel biologic therapies targeting specific inflammatory mediators have shown promise in preclinical and clinical studies for their ability to modulate immune responses and attenuate inflammation in SCD. Given the multifactorial nature of oxidative stress and its intertwined relationship with inflammation, endothelial dysfunction, and vaso-occlusive events in SCD, combination therapy targeting multiple pathways may offer synergistic benefits and improve therapeutic outcomes. Combinatorial approaches integrating antioxidant therapy, NO modulation, anti-inflammatory agents, and disease-modifying treatments such as hydroxyurea represent a rational strategy for addressing the complex pathophysiology of SCD and mitigating oxidative imbalance.

## Conclusion

Unraveling the molecular mechanisms of oxidative imbalance in sickle cell disease (SCD) offers valuable insights into potential therapeutic strategies to mitigate disease complications and improve patient outcomes. The intricate interplay between aberrant erythrocyte function, inflammation, endothelial dysfunction, and impaired antioxidant defenses underscores the multifaceted nature of oxidative stress in SCD pathophysiology. Targeting the molecular pathways involved in ROS production represents a promising therapeutic avenue. Strategies aimed at reducing HbS polymerization, scavenging ROS, or inhibiting ROS-generating enzymes could alleviate oxidative stress and its downstream consequences. Additionally, modulating redox-sensitive signaling pathways, such as nuclear factor erythroid 2-related factor 2 (Nrf2), holds therapeutic potential by enhancing antioxidant defenses and mitigating oxidative damage.

## References

1. Mansour AK, Yahia S, El-Ashry R, Alwakeel A, Darwish A, Alrjjal K. Sickle cell disease (SCD). Inherited Hemoglobin Disorders. 2015;35.
2. Tebbi CK. Sickle cell disease, a review. Hemato. 2022;3(2):341-366.
3. Kaur M, Dangi CB, Singh M. An overview on sickle cell disease profile. Asian J Pharm Clin Res. 2013;6(1):25-37.
4. Vona R, Sposi NM, Mattia L, Gambardella L, Straface E, Pietraforte D. Sickle cell disease: role of oxidative stress and antioxidant therapy. Antioxidants. 2021;10(2):296.
5. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
6. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
7. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.

8. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
9. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences. 2023 Sep 11;6(4):12-17.
10. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
11. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-8.
12. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-0487.
13. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
14. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-0487.
15. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
16. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine. 2023;102(48):e36462.
17. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
18. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
19. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
20. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
21. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
22. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.
23. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
24. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.

25. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
26. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
27. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-5.
28. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
29. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
30. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO. Sickle Cell Anaemia: Current Burden in Africa. International Journal of Innovative and Applied Research. 2023;11(2):12-14.
31. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10; 6 (2): 10-13.
32. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
33. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
34. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3):134-143.
35. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
36. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
37. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
38. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
39. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.

40. Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:58-66.
41. Obeagu EI, Obeagu GU. Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sickle Cell Disease Education. Elite Journal of Health Science. 2024;2(2):7-15.
42. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine. 2024 Feb 9;103(6):e37127.
43. Obeagu EI. Chromium VI: A Silent Aggressor in Sickle Cell Anemia Pathophysiology. Elite Journal of Haematology, 2024; 2 (3).:81-95.
44. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
45. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine. 2024 Jan 12;103(2):e36898.
46. Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science. 2024;2(2):1-9.
47. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.
48. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).
49. Obeagu EI, Obeagu GU. Synergistic Care Approaches: Integrating Diabetes and Sickle Cell Anemia Management. Elite Journal of Scientific Research and Review. 2024;2(1):51-64.
50. Obeagu EI, Obeagu GU. Improving Outcomes: Integrated Strategies for Diabetes and Sickle Cell Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):20-9.
51. Obeagu EI, Obeagu GU. The Role of Parents: Strengthening Adolescent Education for Sickle Cell Disease Prevention. Elite Journal of Public Health. 2024;2(1):15-21.
52. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:67-80.
53. Obeagu EI, Obeagu GU. Overcoming Hurdles: Anemia Management in Malaria-Affected Childhood. Elite Journal of Laboratory Medicine. 2024;2(1):59-69.
54. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024;2(1):33-45.
55. Obeagu EI, Ogunnaya FU, Obeagu GU. Integrated Approaches for Improving Pediatric Health: Addressing Anemia in Malaria Cases. Journal home page: http://www. journalijiar. com.;12(01).
56. Vona R, Sposi NM, Mattia L, Gambardella L, Straface E, Pietraforte D. Sickle cell disease: role of oxidative stress and antioxidant therapy. Antioxidants. 2021;10(2):296.
57. Conran N, Belcher JD. Inflammation in sickle cell disease. Clinical hemorheology and microcirculation. 2018;68(2-3):263-299.
58. Gbotosho OT, Kapetanaki MG, Kato GJ. The worst things in life are free: the role of free heme in sickle cell disease. Frontiers in immunology. 2021; 11:561917.

59. Wang Q, Zennadi R. The role of RBC oxidative stress in sickle cell disease: from the molecular basis to pathologic implications. Antioxidants. 2021;10(10):1608.
60. Nash KM, Ahmed S. Nanomedicine in the ROS-mediated pathophysiology: Applications and clinical advances. Nanomedicine: Nanotechnology, Biology and Medicine. 2015;11(8):2033-2040.
61. Ofori-Acquah SF. Sickle cell disease as a vascular disorder. Expert Review of Hematology. 2020;13(6):645-653.